公司參加2025年美國西部醫(yī)藥原料及植物提取物展覽會 The company participated in the 2025 West Coast Exhibition for Pharmaceutical Ingredients and Plant Extracts in the United States
公司參加2025年美國西部醫(yī)藥原料及植物提取物展覽會
2025年當?shù)貢r間10月29日-30日，美國西部醫(yī)藥原料及植物提取物展覽會在美國拉斯維加斯盛大舉辦，公司董事長羅翀帶業(yè)務團隊攜公司核心產(chǎn)品蘆丁、槲皮素、甘露糖等植物提取物產(chǎn)品亮相展會現(xiàn)場，向全球客商推介公司核心產(chǎn)品及企業(yè)實力。
美國西部醫(yī)藥原料及植物提取物展覽會已成功舉辦27屆，并發(fā)展成為美國規(guī)模最大的天然提取物、保健品原料及食品添加劑行業(yè)的國際性展會。吸引了超1500家企業(yè)參展，其中中國企業(yè)數(shù)量近500家，創(chuàng)下歷屆新高。也是公司開拓國際市場、洞悉行業(yè)前沿、了解技術(shù)與產(chǎn)品進步和發(fā)展趨勢重要平臺。
展會期間，公司展臺前客商絡(luò)繹不絕，業(yè)務團隊以熱情專業(yè)的態(tài)度，向新老客戶詳細介蘆丁、槲皮素、鼠李糖等植物提取物優(yōu)勢產(chǎn)品，與老客戶溝通解決當前合作中遇到的問題困難，商討2026年度新合同訂單，業(yè)務洽談取得積極成果。
北美市場是醫(yī)藥原料最重要的終端市場，引領(lǐng)著行業(yè)發(fā)展方向，是企業(yè)產(chǎn)品加快“走出去”的重要目的地。下一步，公司將錨定國際原料市場需求，以產(chǎn)品質(zhì)量為核心競爭力，以服務保障為合作基石，持續(xù)加大國際市場開發(fā)力度，不斷提升國際化經(jīng)營水平。
The company participated in the 2025 West Coast Exhibition for Pharmaceutical Ingredients and Plant Extracts in the United States
From October 29 to 30 local time, 2025,the West Coast Exhibition for Pharmaceutical Ingredients and Plant Extracts was grandly held in Las Vegas, USA. Chairman Luo Chong led the company's business team to showcase core products—including rutin, quercetin, mannose, and other plant extracts—at the exhibition, promoting the company's flagship offerings and overall capabilities to global buyers.
The West Coast Exhibition for Pharmaceutical Ingredients and Plant Extracts has been successfully held for 27 editions and has grown into the largest international trade show in the United States dedicated to natural extracts, dietary supplement ingredients, and food additives. This year' event attracted more than 1,500 exhibitors, including nearly 500 Chinese companies—a record high in the exhibition's history. For our company, it serves as a vital platform to expand into international markets, gain insights into industry frontiers, and stay abreast of the latest advancements and trends in technology and products.
During the exhibition, the company’s booth was continuously visited by a steady stream of buyers. The business team, with enthusiasm and professionalism, provided detailed introductions to both new and existing clients about the company's key plant extract products—such as rutin, quercetin, and rhamnose. They also engaged in discussions with long-standing customers to address current challenges in their collaborations and negotiated new contracts and orders for 2026, achieving positive outcomes in business discussions.
The North American market is the most important end-market for pharmaceutical ingredients, setting the trend for industry development and serving as a key destination for accelerating the company's global expansion. Going forward, the company will closely align with international demand for raw materials, taking product quality as its core competitive advantage and service reliability as the foundation for collaboration. It will continue to intensify efforts in international market development and steadily enhance its global operational capabilities.